ArticleCureus2025
Small Intestinal Bacterial Overgrowth in Patients With Severe Alcoholic Hepatitis: Frequency and Predictors.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Frequency and predictors of small intestinal bacterial overgrowth in acute pancreatitis.World journal of gastrointestinal pharmacology and therapeutics · 2026Article
- Frequency and Predictors of Small Intestinal Bacterial Overgrowth in Patients with Functional Dyspepsia.Euroasian journal of hepato-gastroenterologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimsSmall intestinal bacterial overgrowth (SIBO) is a gut microbiota-related disorder characterized by excessive bacterial density and/or abnormal microbiota composition in the small intestine. We aimed to evaluate the frequency of SIBO in patients with severe alcoholic hepatitis (SAH) and to identify independent predictors.
methodsWe included 60 consecutive patients with SAH and 30 healthy controls (HC). After an overnight fast, SIBO was evaluated using the glucose hydrogen breath test (GHBT) with 100 g of glucose. A sustained increase in breath hydrogen or methane levels > 12 parts per million (ppm) above the basal level was considered diagnostic for SIBO.
resultsSIBO was more frequent in patients with SAH than HC (15/60 (25.0%) vs. 1/30 (3.3%), p = 0.017). In the univariate analysis, globulin levels, total protein levels, and predominant methane producer status significantly differed between patients with and without SIBO. In the multivariate analysis, the predominant methane producer status increased the risk of SIBO by 17.44 times (adjusted odds ratio: 17.44 (95% CI (1.9-154.04)), p = 0.001).
conclusionsThis study showed that SIBO is a more common finding in patients with SAH than in HC. The predominant methane producer status independently predicted the SIBO in these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.